Ardena, a focused pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) operating in Belgium, Spain, the Netherlands, and Sweden, has finalized its acquisition of Catalent...
Industry experts from the healthcare segment made their remarks post-budget 2025. The budget strengthens India's commitment to health innovation, inclusive growth and improved access to nutrition. The exemption of around 40 life-saving drugs from...
C2 PHARMA has disclosed the approval of a Certificate of Suitability (CEP) for Oxybuprocaine Hydrochloride from the European Directorate for the Quality of Medicines and Health Care (EDQM). Oxybuprocaine Hydrochloride is presently accessible to...
Apogee Therapeutics, Inc., a biotechnology firm in the clinical stage, announced that the initial patient has received treatment in Part B of the phase 2 APEX clinical trial of APG777 for individuals with moderate-to-severe atopic dermatitis (AD)...
Jupiter Neurosciences Inc., a pharmaceutical company in the clinical stage, is developing JOTROL, a patented platform based on resveratrol, and has reached an agreement with Catalent Pharma Solutions LLC to produce JOTROL softgel capsules to...
Akums Drugs and Pharmaceuticals, a leader in contract development and manufacturing, has launched Dapagliflozin + Pioglitazone tablets; an advanced combination therapy designed to tackle the growing challenge of diabetes management...
Ameera Shah’s Metropolis Healthcare Limited, the second-largest and most esteemed pathology laboratory chain in India, announced its partnership with Roche Diagnostics India and surrounding regions to launch the self-sampling human papillomavirus...
Tasso Inc., the premier provider of patient-focused, clinical-grade blood collection solutions, along with ARUP Laboratories, the largest nonprofit clinical and academic reference lab in the U.S., announced their partnership to create and...
Datopotamab deruxtecan (Dato-DXd) has received a recommendation for approval in the European Union (EU) to treat adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast...
Vanda Pharmaceuticals Inc. and AnaptysBio, Inc. announced an exclusive worldwide licensing agreement for the development and marketing of imsidolimab (IL-36R antagonist mAb), which has successfully finished two registration-supporting global Phase...
, CDSCO.jpg)
